Nitric oxide (NO) is crucial in diverse physiological and pathological processes. We show that a hypomorphic mouse model of argininosuccinate lyase (encoded by Asl) deficiency has a distinct phenotype of multiorgan dysfunction and NO deficiency. Loss of Asl in both humans and mice leads to reduced NO synthesis, owing to both decreased endogenous arginine synthesis and an impaired ability to use extracellular arginine for NO production. Administration of nitrite, which can be converted into NO in vivo, rescued the manifestations of NO deficiency in hypomorphic Asl mice, and a nitric oxide synthase (NOS)-independent NO donor restored NO-dependent vascular reactivity in humans with ASL deficiency. Mechanistic studies showed that ASL has a structural function in addition to its catalytic activity, by which it contributes to the formation of a multiprotein complex required for NO production. Our data demonstrate a previously unappreciated role for ASL in NOS function and NO homeostasis. Hence, ASL may serve as a target for manipulating NO production in experimental models, as well as for the treatment of NO-related diseases.
l-arginine is the natural substrate of NOSs for generating NO. As a by-product of the NOS reaction, l-citrulline is formed from l-arginine. Within the cell, citrulline can be recycled back to arginine by the cytoplasmic enzymes argininosuccinate synthase (ASS1) and ASL, constituting the citrulline-NO cycle (Supplementary Fig. 1 ). The availability of intracellular l-arginine is potentially a ratelimiting factor in cellular NO production, in spite of the fact that extracellular and exogenous sources should theoretically be able to replenish NO deficiency. It has been hypothesized that compartmentalization and intracellular metabolite channeling underlies the 'arginine paradox' , in which extracellular and intracellular pools of l-arginine are distinguishable 1 . However, this compartmentalization has yet to be demonstrated in vivo, and its mechanistic basis remains unclear.
Many tissues and cell types contain ASS1 and ASL, providing a cell-autonomous mechanism for generating arginine ( Supplementary  Fig. 1 ). Arginine serves as the precursor for the synthesis of urea, NO, polyamines, proline, glutamate, creatine and agmatine 2 . The regulation of l-arginine availability for these intracellular pathways is celltype and end-product specific; for example, arginine generated by ASL in hepatocytes is directed mostly to urea production, whereas in other cell types its metabolic fate is context dependent 3 .
Argininosuccinic aciduria (ASA) (Mendelian Inheritance of Man (MIM) 207900) is the second most common human urea cycle disorder (UCD) and is caused by deficiency of ASL. Individuals with ASA cannot generate arginine from citrulline. Despite early treatment and adequate metabolic control of hyperammonemia, people with ASA can still have persistent intellectual impairment, delayed motor skills 4, 5 and progressive hepatic disease [6] [7] [8] . Notably, intellectual impairment and liver cirrhosis can be seen in individuals with ASA even in whom treatment was initiated early and who had few, if any, documented episodes of hyperammonemia. Recent reports also suggest that people with ASA are at risk for the development of systemic hypertension 5, 9, 10 . The mechanism behind these unique clinical features, which are not observed in other UCDs, is open to speculation, although a reduction in NO production secondary to a localized deficiency of l-arginine is one possibility. A link between urea cycle function and NO production has been previously suggested by the association of genetic variants in urea cycle genes with NO-related disease processes [11] [12] [13] .
We hypothesized that ASL deficiency would lead to systemic NO deficiency. In addition, because of the inability of supplemental l-arginine to prevent long-term complications in patients with ASA, we investigated whether ASL has a more central role in cellular a r t i c l e s 1 6 2 0 VOLUME 17 | NUMBER 12 | DECEMBER 2011 nature medicine arginine usage for NO synthesis beyond intracellular recycling of citrulline into arginine. We tested our hypothesis in vivo in a hypomorphic mouse model of Asl as well as in humans with ASA, and we complemented our results with in vitro studies using human ASA fibroblasts and primary endothelial cell lines.
RESULTS

Asl hypomorphic mice show evidence of multiorgan dysfunction
We hypothesized that Asl loss would cause deficiency of endogenous arginine production, resulting in reduced NO synthesis. Similar to human neonates with ASA, complete loss of function of Asl results in neonatal hyperammonemia and lethality 14 . Therefore, we generated a conditional hypomorphic allele by introducing a neomycin (neo) selection cassette into intron 9 of the mouse Asl gene ( Supplementary  Fig. 2a-c) . Quantitative RT-PCR, western blot analysis and analysis of Asl enzymatic activity in mice homozygous for the neo insertion (Asl neo/neo ) showed a significant (P ≤ 0.05) reduction in gene and protein expression, with 25% residual RNA, 25% residual protein and 16% residual enzyme activity, demonstrating the hypomorphic nature of this allele ( Supplementary Fig. 3a-c) . Plasma amino acid analysis also showed a profile consistent with Asl deficiency, with elevation of citrulline and argininosuccinic acid levels, two precursor metabolites upstream of the enzymatic block, and reduction of arginine levels, a product metabolite downstream of the enzymatic block ( Supplementary Fig. 3d ). We confirmed that the hypomorphic nature of this allele was the result of the neo cassette insertion, as its Frt-mediated deletion resulted in phenotypically normal mice (Asl flox/flox ) ( Supplementary Fig. 4a ). Asl hypomorphic mice were born at the expected Mendelian ratio but died within the first 3-4 weeks of life from multiorgan failure (Fig. 1a,b) . During the early postnatal period, the dietary supply of arginine from breast milk is insufficient, and thus there is a dependency on endogenous arginine synthesis 15 . The survival of these mice for a few weeks provided us with an opportunity to explore the consequences of impaired endogenous arginine synthesis. Although Asl neo/neo mice were indistinguishable from wild-type (WT) littermates at birth, they showed abnormal hair patterning and significant growth restriction by 2 weeks of age (Fig. 1a,c) . Asl neo/neo mice also showed evidence of multiorgan dysfunction characterized by elevation of liver transaminase levels in plasma, decreased renal creatinine clearance and elevated systolic and diastolic blood pressures as compared to WT mice (Fig. 1d-f) . Histological analyses revealed pathological features in multiple organs, including those in the immune, hematopoietic, renal and cardiovascular systems, that are not attributable to hyperammonemia 16 ( Supplementary Fig. 5a-f) . We noted that some features of this phenotype would be consistent with a systemic disruption of NO homeostasis, as NO has been shown to have a key role in diverse pathological processes including systemic hypertension, immune dysfunction, renal disease and hepatic fibrosis 17, 18 .
Loss of Asl leads to global NO deficiency in mice To determine whether the pathological features observed in the Asl hypomorphic mice were attributable to impaired NO synthesis or altered NO homeostasis, we examined the possibility of a genetic interaction between Asl and Nos3 (encoding nitric oxide synthase 3, also referred to as eNOS) on systemic blood pressure. Whereas neither Nos3 +/− nor Asl neo/+ mice were hypertensive, double-heterozygous Nos3 +/− ;Asl neo/+ mice had significant hypertension (Fig. 1g) , demonstrating a synergystic effect between these two genes.
We assayed tissue levels of nitrite (a NO oxidative product) and the tissue and plasma levels of nitrosothiol (RSNO) as a reflection of NO production and signaling. We found reduced NO production in tissues of Asl neo/neo mice, as reflected by a significant decrease in S-nitrosylation and/or nitrite levels in heart and other tissues (Fig. 2a,b) . In Asl flox/flox mice in which the neo cassette had been excised and Asl expression normalized, tissue RSNO levels were also normal ( Supplementary Fig. 4b,c) . To address whether the loss of Asl led to secondary changes within the NO pathway that might alternatively account for reduced NO synthesis, we measured RNA and protein expression levels of Ass1 (upstream of Asl), the arginine transporter Cat1 and Nos3, as well as other regulators of NO production. We found that their expression in mutant lung and liver was either unchanged or upregulated in the face of Asl loss of function ( Fig. 2c and Supplementary Fig. 6a-c) . Similarly, levels of the endogenous inhibitor of l-arginine, asymmetric dimethyl arginine (ADMA), were also not significantly different in mutant and WT mice (data not shown). Hence, the multiorgan dysfunction observed in Asl-mutant mice was associated with evidence of decreased systemic NO production, the primary cause for which seemed to be the deficiency of Asl.
NO source partially rescues the Asl hypomorphic mice Recent studies show that nitrate and nitrite can be recycled to form NO as an alternative to the classical l-arginine-NOS pathway 19, 20 . If some of the phenotypic consequences of Asl deficiency were due to decreased NO production, normalization of NO status by supplementation with sodium nitrite might be expected to partially correct the phenotype. However, Asl neo/neo deficient mice also have hyperammonemia (secondary to an inability to clear waste nitrogen by urea synthesis in the liver), which presumably contributes to the lethality in these mice. Therefore, we first treated Asl neo/neo mice with either sodium benzoate (250 mg per kg body weight per day) or with l-arginine (100 mg per kg body weight per day), medications which are the standard of care in patients with ASA for prevention of hyperammonemia. Sodium benzoate works by stimulating alternative disposal of glycine containing nitrogen via conjugation, and l-arginine works by priming the urea cycle to generate more argininosuccinic acid, a nitrogen sink that is cleared via urinary excretion. Not surprisingly, we found significantly improved survival in Asl neo/neo mutant mice treated with these drugs (Fig. 3a) , suggesting that, similar to humans with ASA, hyperammonemia is indeed partially responsible for early lethality in this model. Survival improved more with arginine treatment than with sodium benzoate treatment, suggesting that exogenous arginine might have a salutary effect on the arginine deficiency state beyond its effects on nitrogen clearance. Treatment with sodium nitrite, which can be metabolized to form NO 19, 20 , produced a greater survival benefit compared to treatment with either sodium benzoate or arginine ( Fig. 3a and Supplementary Table 1) , arguing for the predominant contribution of NO deficiency to the phenotype. Nitrite supplementation produced comparable survival to the traditional treatment of sodium benzoate plus arginine; however, weight gain was evident only in the nitrite group (Fig. 3b,c) . Notably, triple therapy with the combination of sodium benzoate, arginine and sodium nitrite produced the greatest survival and weight gain (Fig. 3b,c) . Moreover, triple therapy was associated with correction of Kaplan-Meier survival analysis of the arginine-plus-sodium-benzoate-treated group (n = 16), the sodium-nitrite-treated group (n = 27) and the tripletherapy group (arginine, sodium nitrite and sodium benzoate; n = 22), compared to the placebo group (n = 22) (*P < 0.001 on log ranks). (c) Left, weight gain with sodium-nitrite treatment (n = 29) and the tripletherapy treatment (n = 22) as compared to placebo (n = 26) and to the liver protein nitrosylation to levels higher than those observed in WT mice and led to normalization of blood pressure (Fig. 3d,e) .
Arginine treatment does not prevent cellular NO deficiency
To evaluate NO insufficiency at a tissue level in Asl neo/neo mice, we performed aortic ring relaxation measurements. In contrast to WT mice, aorta from Asl neo/neo mice showed evidence of significant endothelial dysfunction, as shown by an inability of preconstricted aortic rings to relax in response to acetylcholine (Fig. 3f,g ). Furthermore, preconstricted aortic rings from neither WT nor Asl neo/neo mice responded to arginine treatment. A lack of response in WT rings ex vivo was expected, as WT vascular tissues have intracellular l-arginine levels that are higher than the K m for NOS3 (refs. 21-23) . However, this result was surprising in Asl neo/neo rings, given their low intracellular levels of arginine. In contrast, Asl neo/neo preconstricted aortic rings relaxed in response to sodium nitroprusside, a NOS-independent NO donor ( Fig. 3g) , demonstrating the integrity of the vascular preparation and a functional signaling pathway downstream of NO.
To further evaluate the requirement of Asl for NO synthesis, we knocked down its expression using RNAi in primary piglet endothelial cells (Fig. 4a,b) . Asl knock down in these endothelial cells led to significantly less NO production in response to inducers such as bradykinin and L-arginine (Fig. 4c,d ).Together, these data underscore the requirement of Asl for the production of NO at the organism, tissue and cellular levels.
ASA cells have deficiency of NOS-dependent NO production
These findings would predict that humans with ASA should also be deficient for markers of NO synthesis in spite of normal or even elevated levels of extracellular plasma arginine that result from the standard-of-care therapeutic arginine supplementation. To assess the role of ASL in NO synthesis in humans, we studied fibroblasts from human subjects with ASA disease with null ASL enzymatic activity. First, we verified that primary human fibroblasts express both NOS2 and NOS3 (Supplementary Fig. 7a ). As expected, the expression level of NOS3 was significantly lower in the fibroblasts as compared to human umbilical vein endothelial cells, whereas that of NOS2 was comparable in the two cell types (Supplementary Fig. 7a ). In addition, as previously published [24] [25] [26] , we established that NOS activity exists in primary human fibroblasts, which can be activated by treatment with the NOS cofactor tetrahydrobiopterin (BH 4 ) and inhibited by treatment with a NOS inhibitor (Supplementary Fig. 7b) . Despite similar expression of other NO synthetic proteins (Supplementary Fig. 7c,d) , addition of l-arginine (1 mM) to the culture medium of primary fibroblasts from control subjects for either 30 min or 24 h resulted in significant increases in RSNO, nitrite and cGMP production as compared to fibroblasts from subjects with ASA, reflecting an increase in NO synthesis from NOS in control but not ASA subjects (Fig. 5a,b and Supplementary Fig. 7e,f) . The viability of cells from controls and subjects with ASA was comparable, and intracellular arginine levels were effectively and similarly increased by l-arginine supplementation (data not shown), yet normal NO synthesis did not occur in the absence of ASL protein.
Defective arginine use for NO synthesis in subjects with ASA In spite of elevations in the concentrations of plasma arginine (as a consequence of therapeutic supplementation) and citrulline (that accumulates upstream of the block), subjects with ASL deficiency had significantly decreased concentrations of plasma RSNO and nitrite as compared to healthy control subjects (Fig. 5c) . To directly measure NO production and trace the contribution of extracellular arginine to NO conversion, we performed stable isotopic flux measurements in control subjects and subjects with ASA on a steady-state nitrite and protein-intake diet. Using a two-day multitracer protocol, we found increased arginine and urea appearance (flux) rates in subjects with ASA owing to pharmacological treatment with l-arginine (Fig. 5d) . We also found increased citrulline flux and fractional transfer of 15 N label from 15 N-glutamine to 15 N-citrulline (Fig. 5d ) that can be explained by the accumulation of this metabolite upstream of the block in ASL. However, consistent with the decreased plasma RSNO levels and the mouse and cellular data, we found decreased 15 N transfer from infused 15 N 2 -guanidino-labeled arginine to 15 N-citrulline, a surrogate marker for NO production (Fig. 5d) . Our data suggest that the decrease in NO production in vivo is attributable to an inability both to recycle intracellular citrulline into arginine for endogenous synthesis and to channel extracellular plasma arginine for NO production. These human data further support the concept that, in the absence of ASL, extracellular arginine (the source of the isotopic label) is inefficiently converted to citrulline to form NO. Hence, ASL deficiency may result in deficient NO synthesis from both intracellular and extracellular sources of arginine.
To evaluate the functional consequences of this observation in vivo, we performed vessel reactivity assays in pediatric subjects with ASA. We examined the vasodilatory response of the brachial artery via Doppler ultrasound following transient occlusion of flow as a measure of NOS-dependent vascular relaxation, as well as the vasodilatory response following sublingual nitroglycerin as a measure of NOS-independent vascular relaxation (Fig. 5e) . In healthy controls, vascular dilation measurements after both interventions were equivalent, and the magnitude of the responses was similar to those previously reported 27 . In contrast, subjects with ASA failed to show any NOS-dependent vascular relaxation after release of vessel occlusion. However, they responded similar to controls after administration of sublingual nitroglycerin (Fig. 5e) , showing normal response to an exogenous, NOS-independent source of NO. Notably, the near absence of flow-mediated relaxation, a measure of NO mediated dilation, has not been reported in other pediatric diseases. These results corroborate with the aortic ring experiments in the hypomorphic Asl mouse model in supporting the conclusion that although signaling downstream of NO is intact, loss of ASL limits NOS-dependent NO production, leading to loss of NOS-dependent vascular reactivity.
ASL requirement for NOS multiprotein complex
Direct biochemical interactions among the component proteins of a compartmentalized NOS complex could explain metabolite channeling 28, 29 . The three key protein components responsible for recycling citrulline into NO are ASS1, ASL and NOS, and their expression levels are coordinately regulated 30 . Several studies have shown either interaction or co-localization of these three proteins [28] [29] [30] [31] . Notably, an interaction between NOS3 and the cationic amino acid transporter CAT-1 responsible for arginine transport was recently described in endothelial cells 31 .
We first verified that such interactions among proteins in the NOS complex exist by performing a mass spectrometry analysis of proteins immunoprecipitated with an antibody to Ass1, using lysates of lipopolysaccharide-stimulated RAW246.7 cells. This analysis showed that Ass1-specific antibody in addition to Ass1, was able to pull down Nos2, Asl and Hsp90, confirming the existence of these proteins in a complex (Supplementary Table 2) . We tested the relevance of these findings ex vivo by performing immunoprecipitation with an antibody to Ass1 using lysates of lung and brain tissues from WT mice. Our results show that Ass1 was able to pull down Nos3 and Nos1 together with the other protein complex components in lungs and brain, respectively ( Fig. 6a and Supplementary Fig. 8) . Together with the mass spectrometry data, our results support the existence of a Nos-containing multiprotein complex for all three Nos isoforms.
To determine the effects of partial loss of Asl on this protein complex, we compared the component proteins co-immunoprecipitated by antibody to Ass1 in WT and Asl neo/neo mice. As individuals with ASA have hypertension and intellectual delays that are independent of hyperammonemic episodes, we focused our studies on the effect of Asl deficiency on complex formation between Asl and Nos3 or Nos1, which are mainly expressed in endothelial and neuronal cells, respectively. As assessed by immunoprecipitation using an antibody to Ass1, Asl neo/neo mouse lung and brain tissue showed significantly decreased quantities of Nos3 and Nos1, respectively, in the NOS complex, as well as decreased levels of Hsp90 and Cat1 in this complex ( Fig. 6a and Supplementary Fig. 8 ). This decrease in immunoprecipitates occurred despite the increased levels of these individual proteins (other than Asl) in tissues of Asl neo/neo mice as assessed by western blot analysis ( Fig. 2c and Supplementary Fig. 8 ). These data support a central requirement for Asl in the formation of the NOS complex.
To dissect the structural requirement for ASL in NOS complex formation from its catalytic activity, we tested NOS complex assembly using a mutated form of human ASL that contains an amino acid Figure 5 ASL-deficient human subjects and cells do not efficiently generate NO from extracellular arginine. (a) Change in RSNO production (∆RSNO) in control versus ASA fibroblasts supplemented with l-arginine (1 mM) for 24 h (*P < 0.05). The experiment was repeated three times. (b) Change in nitrite production (∆Nitrite) in control versus ASA fibroblasts in response to the indicated treatments over 30 min (ANOVA, *P < 0.05, **P < 0.0005). The experiment was repeated three times. (c) Plasma arginine, citrulline (Cit), nitrite and RSNO concentrations in human subjects with ASA (n = 3) as compared to controls (n = 3) (*P < 0.05, **P < 0.005, ***P < 0.0005). (d) Dynamic metabolite flux measurements in subjects with ASA versus control subjects. Left, arginine and urea flux in subjects with ASA (n = 3) versus controls (n = 3). Gln is a marker for increased nitrogen load and is typically increased in hyperammonemia. The Gln flux is shown to demonstrate that the subjects with ASA were stable without metabolic decompensation. Right, citrulline flux, fractional transfer of the amido-nitrogen from 15 N-glutamine to 15 N-citrulline, and fractional transfer of guanidino nitrogen from 15 N 2 -arginine to 15 N-citrulline (a marker of NO production) in subjects with ASA compared to controls, (Gln, glutamine; Cit, citrulline; Arg, arginine) (*P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.00005). substitution, R236W, affecting its catalytic site 32 (Fig. 6b) . This mutation abolishes the enzymatic activity of ASL (that is, the cleavage of argininosuccinic acid) but does not abolish its tertiary structure 33, 34 . Overexpression of this mutant form of ASL together with NOS3 in COS7 cells did not prevent NOS3 protein assembly with ASS1, as shown by immunoprecipitation with antibodies against ASS1 or NOS3. However, consistent with our findings in Asl neo/neo mice, overexpression of NOS3 together with an empty vector (without ASL), prevented efficient co-immunoprecipitation of the proteins involved in the NOS complex, as assessed using either one of these antibodies (Fig. 6b) .
To test whether this structural requirement for ASL in NOS complex formation is in fact essential for the usage of extracellular arginine for NO production, we transduced ASA-mutant human fibroblasts null for ASL activity with lentivirus expressing either WT human ASL or human ASL with an amino substitution in the catalytic domain, R113Q 32 . Similarly to R236W, the R113Q substitution abolishes the catalytic activity of ASL without affecting ASL protein stability 32, 35 . If there is a structural requirement for ASL in a NOS complex for channeling of extracellular arginine to NOS, the mutated form of ASL would be expected to restore NO production in response to extracellular arginine in ASA-mutant cells despite its lack of catalytic activity. Indeed, overexpression of R113Q ASL restored nitrite generation at a level comparable to that in control cells when both cells were supplemented with arginine (Fig. 6c) .
This structural requirement for an ASL-dependent NOS complex helps to explain our physiological and cellular observations, suggesting that in the absence of ASL, there is less efficient formation of a NOS multiprotein complex leading to decreased NO production from both endogenously synthesized and exogenously channeled arginine (Fig. 6d) .
DISCUSSION
Our findings show that decreased ASL abundance leads to loss of NOS complex formation associated with NO deficiency at the whole-organism, tissue and cellular levels in both humans and mice. These data support a requirement for ASL not only for the synthesis of intracellular arginine but also for the use of extracellular arginine for NOS-dependent NO synthesis. We hypothesize that the structural basis for metabolite channeling in this context is, at least in part, the existence of an intracellular complex of proteins containing NOS. Our studies were prompted by clinical observations in people with ASA. First, the natural history of ASL-deficient humans suggested the presence of organ dysfunction and complications independent of hyperammonemia caused by hepatic urea cycle deficiency. This led us to hypothesize alternative mechanisms of injury, including deficiency of NO secondary to loss of citrulline recycling or endogenous arginine production. However, this could not alone explain the phenotypic complexity because patients with ASL are replete with extracellular arginine from pharmacological supplementation.
This conceptual difficulty was also highlighted by the finding that subjects with ASA had decreased markers of NO production (plasma RSNO and nitrite). Subjects with ASA, ASA fibroblasts and primary endothelial cells made Asl deficient by siRNA knockdown were also unable to efficiently generate NO after extracellular arginine supplementation. In humans with ASA, this inability to generate NO from extracellular arginine was apparent based on dynamic measurements of arginine to citrulline flux; in addition, in primary fibroblasts from ASA individuals, this defect was demonstrated via measurement of nitrite, cGMP or both. This NO deficiency was found to be tissue autonomous in the sense that preconstricted aortic rings from mutant mice relaxed in response to NO donors but not arginine; similarly, humans with ASA showed abnormal flow-mediated vascular relaxation that was restored by nitroglycerin. On the whole-organism level, provision of a NO-independent source of NO in the form of nitrite therapy markedly prolonged survival of hypomorphic Asl mice while also restoring tissue nitrosylation and normalizing blood pressure.
The inability of ASL-deficient humans, tissues and cells to use extracellular arginine for NO production occurred despite apparently adequate expression of all other protein components necessary for NO production, including CAT1, ASS1, HSP90 and NOS. Loss of ASL resulted in the decreased abundance of a NOS complex which depends on the structural integrity, but not enzymatic function, of ASL, as shown using catalytically inactive forms of ASL. Together, these studies distinguish two essential roles for ASL: first, the recycling of citrulline in the cell for cell-autonomous arginine synthesis; and second, the maintenance of a NOS complex required for efficient NO production from extracellular sources of arginine. The former depends on the catalytic function of ASL, whereas the latter requires its structural integrity. This model is consistent with distinct evolutionary roles of ASL in other species as in the lens of ducks, which contains δ1 and δ2 crystallin, proteins which are homologous to Asl. Both crystallin isoforms are the products of a gene duplication event of the ancestral ASL gene 36 ; whereas δ2 preserves ASL catalytic activity, δ1 is enzymatically inactive and thought to have structural refractive properties necessary for the lens 36, 37 .
Because NO deficiency is evidenced in the face of excess arginine, it is likely that the primary dysfunction in human with ASA deficiency is at the level of an NO metabolon: insufficient channeling of arginine due to loss of an ASL-NOS complex leads to decreased NO production. A key question for future studies is whether the loss of arginine channeling leads to NOS uncoupling and a consequent increase in free radical stress.
Clinically, these data suggest that the vascular dysfunction and perhaps also the intellectual disability seen in humans with ASA may be partly due to NO insufficiency, and, hence, treatment with a NOS-independent source of NO (for example, sodium nitrite) or NO donors may be beneficial in the long term. Moreover, the clinical variability seen in patients with ASA may depend on the differential effects of specific mutations on ASL catalytic versus structural functions, that is, NO deficiency may be variably found in the population of humans with ASA depending on the effect of mutation on protein structure.
These data also have broader implications for NO biology and disease. Mechanistically, they support intracellular compartmentalization as an explanation for the arginine paradox, that is, the increased production of NO with the addition of extracellular arginine despite apparently saturating intracellular arginine levels. Moreover, they suggest an explanation as to why the arginine paradox is not observed with ASL deficiency. As such, ASL may serve as the linchpin in NO production. Hence, inhibition of ASL in a cell-specific fashion may be an effective way to probe NO function in vivo, independent of potential NOS redundancy. Similarly, ASL may serve as a new target for manipulating NO production in a cell-autonomous fashion in human disease processes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METHODS
Physiological studies. For mouse generation, gene targeting was performed and verified according to the published protocol using AB2.2 embryonic stem cells 38, 39 , which were injected to C57Albino mice embryos 40 . In all experiments, WT controls were littermate controls. The sequence of the oligonucleotide probes used for construct verification by PCR and Southern blotting are available in the Supplementary Methods. Vascular studies. For wire myography, mice were anesthetized with isoflurane. A thoracotomy was performed to expose thoracic and abdominal aorta. A 25-gauge syringe was inserted into the apex of the left ventricle and perfused free of blood with oxygenated Krebs Henseleit buffer (prepared fresh daily). The right atrium was cut to provide an exit for blood. The aorta was removed and cleaned of fat and adventitia. The aorta was cut into 2-mm-long segments and mounted on a four-channel wire myograph (AD Instruments). Vessel rings were maintained in 10-ml organ baths with oxygenated Krebs buffer (95% O 2 and 5% CO 2 ) (Matheson Tri-gas) at 37 °C. Rings were allowed to equilibrate for 80 min with the buffer in each organ bath changed every 20 min. One gram pre-tension was placed on each aortic ring (appropriate starting tension for optimal vasomotor function as determined in previous experiments (data not shown)). An eightchannel octal bridge (Powerlab) and data-acquisition software (Chart version 5.2.2) were used to record all force measurements. After equilibration for 80 min, 1 µM phenylephrine was added to each ring for submaximal contraction. After stabilization, increasing concentrations of acetylcholine were added to each bath to determine endothelium-dependent relaxation, which was expressed as percentage reversal of phenylephrine-induced constriction.
Blood pressure measurements were performed using tail cuffs. Mice were trained for 2 h to acclimate to the measurement equipment to minimize stress during the experiments. An inflatable-pressure cuff was placed around the tail, and a distal sensor was used to record the blood pressure. Blood pressures were recorded three times for each mouse, giving ten measurements each time over a ten minute period of time (Visitech BP 2000).
Doppler ultrasound flow-mediated relaxation was measured as previously published 27 .
Nitric oxide studies. Nitrate and nitrite concentrations were quantified by ion chromatography (ENO20 Analyzer; Eicom). Biological specimens collected from anesthetized mice were analyzed for nitroso species products of NO as detailed elsewhere 41, 42 . cGMP was measured by ELISA. Equal numbers of cells (7.5 × 10 5 ) from two control and two subject fibroblast lines were plated onto 60 × 35 mm culture plates and grown to confluence in α-MEM containing 20% FBS, 2 mM ml −1 l-glutamine, 100 IU ml −1 penicillin and 100 µg ml −1 streptomycin (Invitrogen). The cells were then incubated with 100 µM Zaprinast (Cayman Chemicals), a phosphodiesterase type V inhibitor, for 30 min. The medium was changed to serum-free α-MEM and 100 µM ascorbic acid 43 (Sigma) , and 100 µM BH 4 (ref. 44) (Sigma) and 500 µM l-NMMA (Biotium) were added as appropriate. Culture medium and cell samples were obtained at 0 and 10 min time points, and their cGMP concentrations were assayed after acetylation using the cGMP EIA Kit (Cayman chemicals) according to the manufacturer's instructions. All samples were run in duplicate, and the average absorbance values were used to calculate the concentrations of cGMP. The net production of cGMP was calculated by subtracting the baseline levels from those at 10 min.
Tissue NO products and metabolite determination. Mice were anesthetized with isoflurane. Venous blood was collected from the inferior vena cava with a 25-gauge needle. After blood withdrawal, a thoracotomy was performed, and a 25-gauge needle was inserted into the apex of the left ventricle, which was perfused with air-equilibrated PBS supplemented with N-ethylmaleimide (NEM) 10 mM and EDTA 2.5 mM for full blood exchange. The right atrium was cut open to provide an exit port for blood and buffer. After 30 s of perfusion, the heart was excised followed by the liver. Excised tissues were blotted dry on filter paper, weighed, cut into small pieces and homogenized immediately in ice-cold NEM and EDTA-containing perfusion buffer. The addition of NEM and EDTA served the purpose of blocking SH groups and inhibiting transition metal-catalyzed transnitrosation reactions, preventing artificial nitrosylation, as well as thiolate-and ascorbate-mediated degradation of endogenous RSNOs 45 . Biological specimens collected from anesthetized mice were analyzed for nitroso species and oxidation products of NO as detailed elsewhere 41, 42 . Nitrate and nitrite concentrations were quantified by ion chromatography (ENO20 Analyzer; Eicom) 41, 46 . Plasma was obtained by centrifugation at 800g at 4 °C for 10 min.
We calculated nitrite production with the following equation: ∆nitrite = nitrite at time x -nitrite at time 0. This calculation was used to compare nitrite production between any time point to the baseline level at time 0 in the medium of the same well.
To assess treatment efficiency, relative nitrite levels were calculated by the following equation: relative nitrite levels = (nitrite levels with treatment at x timenitrite levels at time 0) / (nitrite levels with no treatment at x time -nitrite levels at time 0). RSNO production (∆RSNO) was calculated by subtracting the levels of metabolite at time 0 from the levels at 24 h. Experiments were performed using both genders in humans and mice.
Statistical analyses. Data are expressed as mean values ± s.d. Statistical significance was computed using the Student's two-tailed t test, ANOVA and log-rank. P < 0.05 was considered statistically significant. Survival curves were analyzed based on log-rank tests.
Additional methods. Detailed methodology is described in the Supplementary Methods.
